Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurface Transforms Regulatory News (SCE)

  • This share is currently suspended. It was suspended at a price of 0.112
  • There is currently no data for SCE

Trading & Operational Update

4 Dec 2018 07:00

RNS Number : 2966J
Surface Transforms PLC
04 December 2018
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Surface Transforms plc.

("Surface Transforms" or the "Company")

Trading & Operational Update

Surface Transforms (AIM: SCE) provides the following trading update for the six months to 30 November 2018.

Revenues for the period were £509k (2017: £524k). The cash balance at 30 November was £744k (2017: £3.3m) to which can be added an expected R&D tax credit in excess of £500k, expected to be received in December 2018.

The Company expects to report its interim results for the six months ended 30 November in February 2019.

Progress with Potential OEM Customers

The Company continues to test products with customers as described in recent announcements and is making particularly good progress with German OEM5. Having reviewed the Company's quality processes, logistics capability, financial strength and capacity plan, German OEM 5 has approved Surface Transforms as a potential supplier to them. The Company has been informed, "… it is now officially possible for (OEM 5) to place orders under the condition that the development department is happy with the required performance of ST discs". In respect to engineering approval, test track testing is underway and on schedule. To save later car development time, OEM5 has indicated to Surface Transforms that it intends to approve, at this stage, a pad/disc combination with a new environmentally friendly pad; this new pad requirement is lengthening the test programme and therefore engineering sign off is now expected in early 2019, still within the nomination time frame on the target vehicle.

The work on passing the OEM 3 rig test is also continuing with good progress having been made on understanding the reason for process variability. This work is expected to complete in the first quarter of calendar 2019, consistent with the next round of nomination dates.

Progress with New Capital Equipment

The Company has been awarded the environmental standard ISO 14001 ahead of schedule.

The final furnace for OEM production cell one has successfully completed a number of production runs at the supplier's premises and will now be dismantled and shipped to Knowsley during the next 8 weeks.

These extensive production trials, in combination with a supplier change on a key component, have had the effect of building significant work-in-progress inventory (approx. £200k increase in the period). This excess will unwind over the next 18 months but, obviously, the recent increase and projected decrease in inventory, impacts both current cash and cash projections.

The other furnaces are either in production or finalising software installation. The Company expects OEM cell one to be operational in in summer 2019.

Outlook

The start of production ("SOP") of British OEM6 had been forecast for the final quarter of the Company's FY 2018/19. The Board is increasingly concerned of a possible, but not yet certain, three to six months delay to the SOP. The delay, if it happens, would likely reduce FY 2018/19 sales by £500k. As a precaution, the Company has modelled the working capital impact of this as well as a "stress test" of FY 2018/19 sales simply repeating last year's sales. In both instances the Company has adequate cash headroom. It is additionally worth noting that a delay in SOP does not of course change the medium-term cash projections as this is a limited edition contract for a specific number of cars which have been pre sold, and which, for regulatory reasons need to be produced before December 2020.

Nonetheless, in the light of this, and as a matter of prudence, the Company has revised its FY19 projections based on a delayed scenario of the British OEM 6 limited edition track car, such revenues being deferred to subsequent periods.

For enquiries, please contact:

Surface Transforms plc. +44 151 356 2141

David Bundred, Chairman

Kevin Johnson, CEO

Michael Cunningham CFO

Cantor Fitzgerald Europe (Nomad & Joint-Broker) +44 20 7894 7000

David Foreman, Richard Salmond, Michael Boot (Corporate Finance)

Caspar Shand-Kydd, Gregor Paterson (Sales)

finnCap Ltd (Joint-Broker) +44 20 7220 0500

Ed Frisby / Giles Rolls (Corporate Finance)Richard Chambers (Corporate Broking)

For further Company details, visit www.surfacetransforms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBRBDDCDGBGIX
Date   Source Headline
1st May 20207:00 amRNSResult of over-subscribed open offer
24th Apr 20204:17 pmRNSHolding(s) in Company
23rd Apr 202011:35 amEQSHardman & Co Research: Q&A with Mike Foster on Surface Transforms (SCE): High visibility for 2021 onwards; equity raise
21st Apr 20207:00 amRNSOpen Offer application form - update
20th Apr 202010:20 amRNSHolding(s) in Company
17th Apr 20203:15 pmEQSHardman & Co Research: Surface Transforms (SCE): High visibility for 2021 onwards; equity raise
9th Apr 20203:00 pmRNSPlacing and Open Offer
27th Mar 20207:00 amRNSDeferral of Publication of Results &COVID19 Update
28th Feb 20207:00 amRNSUnaudited interims for the 6 m/e 30 November 2019
10th Feb 20208:27 amRNSHolding(s) in Company
28th Jan 20205:30 pmRNSAppointment of Sales Director and Grant of Options
27th Jan 20202:00 pmRNSDirector/PDMR Shareholding
10th Jan 20207:00 amRNSTrading and operational update
5th Dec 20197:00 amRNSGrant of options
13th Nov 20198:33 amRNSExercise of options
13th Nov 20198:27 amRNSResult of AGM
6th Nov 201910:01 amRNSHolding(s) in Company
6th Nov 20199:00 amRNSExercise of Options and PDMR Dealing
25th Oct 201912:56 pmEQSHardman & Co Research : Surface Transforms (SCE): Recent major contract wins transform prospects
17th Oct 20197:00 amRNSPosting of Annual Report and Notice of AGM
2nd Oct 201910:55 amRNSDirector/PDMR Shareholding
26th Sep 20197:00 amRNSContract award from OEM 1
19th Sep 20197:00 amRNSCapital Markets Day
18th Sep 201910:50 amRNSHolding(s) in Company
9th Sep 20197:00 amRNSPreliminary results and notice of AGM
5th Sep 20194:10 pmEQSHardman & Co Research: Surface Transforms (SCE): Rapid acceleration - 'game-change' announcements
27th Aug 20197:00 amRNSContract Agreement with German OEM 5
15th Aug 20197:00 amRNSChange of Financial Year End Date
16th Jul 20197:00 amRNSContract award from German OEM 5
28th Jun 20197:00 amRNSContract Awards and Commercial Settlement
16th May 20197:00 amRNSDirector/PDMR Shareholding
7th May 20199:05 amRNSSecond Price Monitoring Extn
7th May 20199:00 amRNSPrice Monitoring Extension
7th May 20197:00 amRNSTrading Update
28th Mar 20197:00 amRNSDirector/PDMR Shareholding
25th Mar 20195:05 pmRNSHolding(s) in Company
20th Mar 20197:00 amRNS£1.9 million placing
26th Feb 20197:00 amRNSInterim Results
11th Dec 20185:36 pmRNSResult of AGM
6th Dec 20187:00 amRNSExercise of Options and Director Dealing
5th Dec 20187:00 amRNSGrant of Options
4th Dec 20187:00 amRNSTrading & Operational Update
17th Sep 20187:00 amRNSPreliminary Results and Notice of AGM
10th Sep 20187:00 amRNSBoard appointment
4th Jul 20183:19 pmRNSGrant of options
3rd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20188:38 amRNS£1.5 Million Placing
13th Jun 20187:00 amRNSPre Close Trading, Customer and Operations Update
10th May 20187:00 amRNSDirector/PDMR Shareholding
12th Apr 20187:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.